TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance

Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the best mid-cap growth stocks to buy right now. On January 8, TD Cowen raised its price target on Halozyme to $90 from $79 and kept a Buy rating. Ahead of Q4 2025 earnings, the firm adjusted price targets within the diagnostic tools group and noted that investor sentiment is beginning to shift positively. 2026 guidance will be key for investors looking to position themselves for a sector-wide recovery.

On the same day, Takeda and Halozyme Therapeutics announced a global collaboration and exclusive license agreement. The partnership grants Takeda exclusive access to Halozyme’s proprietary ENHANZE drug-delivery technology for use with vedolizumab, which is marketed globally as ENTYVIO. Vedolizumab is a biologic therapy approved for treating adults with moderately to severely active ulcerative colitis and Crohn’s disease, with total global exposure surpassing one million patient years to date.

The agreement was finalized in December 2025 and provides Takeda with Halozyme Therapeutics Inc.’s (NASDAQ:HALO) recombinant human hyaluronidase PH20 enzyme to facilitate the subcutaneous delivery of vedolizumab. By integrating this commercially validated technology, Takeda aims to offer patients greater treatment flexibility and reduced time spent on therapy management.

Halozyme Therapeutics Inc. (NASDAQ:HALO) is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and devices in the US and internationally.

While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.